Products from BPS Bioscience require a minimum order value above 400€
Application: Negative control in PSMA imaging and radioligand binding studies. Control in the development of ADCs (antibody drug conjugates), CAR-Ts, and BiTEs (bispecific T-cell engagers) targeting PSMA.
Background: PSMA (Prostate-Specific Membrane Antigen, also known as Folate hydrolase 1 or FOLH1) is highly expressed in prostate cancer cells and is used as a prognostic indicator of prostate cancer. The enzyme has folate hydrolase and peptidase activity. PSMA/FOLH1 is used in the clinic as a target for PET (positron emission tomography) imaging of prostate cancer, and as a therapeutic target for radiopharmaceuticals. It is also expressed in other tumor types and in a few normal tissues. PSMA is the target of CAR (chimeric antigen receptor)-T cells and bispecific antibodies currently under development.
Description: PSMA Knockout 22Rv1 Cell Line is a human prostate carcinoma epithelial 22Rv1 cell line in which PSMA (Prostate-Specific Membrane Antigen, also known as Folate hydrolase 1 or FOLH1) has been genetically removed using CRISPR/Cas9 genome editing with a lentivirus encoding the CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human PSMA. This cell line has been validated by genomic sequencing and flow cytometry.
Host Cell Line: 22Rv1, Human epithelial, prostate carcinoma cells, adherent.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (#79796)
Target: PSMA
Uniprot: Q04609
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-2
Deutsch
English
